Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Thomas Malley Sells 50,129 Shares

Key Points

• Director Thomas Malley sold 50,129 shares of Kiniksa Pharmaceuticals at an average price of $33.32, resulting in a total transaction of approximately $1.67 million, marking a 79.98% decrease in his ownership of the stock.
• Kiniksa Pharmaceuticals reported $0.23 earnings per share for the latest quarter, surpassing the consensus estimate by $0.05, with a total revenue of $156.80 million.
• The stock has recently been rated as a "strong-buy" by Wall Street Zen, with a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Thomas Malley sold 50,129 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $33.32, for a total transaction of $1,670,298.28. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $418,032.72. This represents a 79.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Thomas Malley also recently made the following trade(s):

• On Thursday, August 14th, Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97.
• On Tuesday, August 12th, Thomas Malley sold 49,407 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $32.40, for a total transaction of $1,600,786.80.

Kiniksa Pharmaceuticals International Stock Down 1.1%

Shares of Kiniksa Pharmaceuticals International stock traded down $0.37 on Thursday, hitting $33.28. The stock had a trading volume of 474,071 shares, compared to its average volume of 695,957. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $33.98. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of 832.21 and a beta of 0.14. The stock's 50-day simple moving average is $29.22 and its two-hundred day simple moving average is $24.83.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock valued at $9,744,000 after purchasing an additional 9,654 shares during the last quarter. Wells Fargo & Company MN grew its stake in Kiniksa Pharmaceuticals International by 54.7% in the fourth quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after purchasing an additional 7,463 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $3,955,000. Barclays PLC grew its stake in Kiniksa Pharmaceuticals International by 11.2% in the fourth quarter. Barclays PLC now owns 71,896 shares of the company's stock valued at $1,423,000 after purchasing an additional 7,267 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Kiniksa Pharmaceuticals International by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.